Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
7.23
-0.29 (-3.86%)
Nov 16, 2026, 4:00 PM EST - Market closed

Immunic Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
------
Revenue Growth
------
Gross Profit
------
Operating Income
-135.26-103.23-98.05-99.22-86.52-74.42
Net Income
-128.3-97.17-100.51-93.61-120.41-92.95
Earnings Per Share
-3.80-6.24-10.03-21.12-37.84-39.30
EPS Growth
------

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
131.9615.4835.6746.67116.3786.86
Total Debt
-0.5811.331.560.99
Net Cash (Debt)
131.9614.9134.6645.34114.8185.87
Net Cash Growth
284.28%-57.00%-23.55%-60.51%33.70%-32.10%
Net Cash Per Share
3.910.963.4610.2336.0836.30

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-95.97-85.81-84.77-70.83-65.14-83.23
Capital Expenditures
-0.37-0.16-0.26-0.33-0.11-0.07
Free Cash Flow
-96.34-85.97-85.03-71.16-65.26-83.3
Free Cash Flow Growth
------

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
------
Operating Margin
------
Profit Margin
------
FCF Margin
------

Valuation

Selected indicators aren't available for this stock.